08:00 , Jan 11, 2016 |  BioCentury  |  Finance

All-in endocrine

New biological insights into Atterocor Inc .'s lone compound combined with asset sleuthing by founding VC Frazier Healthcare have morphed the company into Millendo Therapeutics Inc. , an endocrine play with a pair of first-in-class...
02:08 , Jan 6, 2016 |  BC Extra  |  Top Story

Millendo raises $62M series B, gains AZ asset

Millendo Therapeutics Inc. (Ann Arbor, Mich.) raised $62 in a series B round led by New Enterprise Associates. Other new investors Roche Venture Fund, Adams Street Partners, Altitude Life Science Ventures, Longwood Fund and Renaissance...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Atterocor management update

Atterocor Inc. , Ann Arbor, Mich.   Business: Cancer   Hired: Pharis Mohideen as CMO, formerly VP of clinical development at Shionogi & Co. Ltd. 's Shionogi Inc. U.S. company  ...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Sterol O-aceyltransferase 1 (SOAT1; ACAT1); b-amyloid (Ab); Ab42 Cell culture and mouse studies suggest inhibitors of ACAT1 could help treat AD by...
02:05 , Oct 11, 2014 |  BC Extra  |  Company News

Management tracks

Roth Capital Partners named John Chambers vice-chairman. Chambers, who joined ROTH in 2009, remains head of its healthcare investment banking group. He was previously the head of the healthcare and investment banking team at Merriman...
07:00 , Apr 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Sterol O-aceyltransferase 1 (SOAT1; ACAT1) Studies in patient samples, mice and cell culture suggest inhibiting ACAT1 prevents cholesteryl ester (CE) synthesis and could...
08:00 , Nov 4, 2013 |  BioCentury  |  Emerging Company Profile

Atterocor: Attacking ACC

The only drug approved to treat adrenal cortical cancer - Lysodren mitotane - is a derivative of DDT with severe side effects and pharmacokinetic challenges. Atterocor Inc. was spun out by the University of Michigan...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

ATR-101: Phase I started

Atterocor began an open-label, U.S. Phase I trial to evaluate ascending doses of oral ATR-101 in about 21 patients. Atterocor also said ATR-101 received Orphan Drug designation in the U.S. and EU. Atterocor Inc. ,...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Financial News

Atterocor completes venture financing

Atterocor Inc. , Ann Arbor, Mich.   Business: Cancer   Date completed: 8/3/12   Type: Venture financing   Raised: $16 million   Investors: Frazier Healthcare Ventures; 5AM Ventures  ...
00:46 , Aug 4, 2012 |  BC Extra  |  Financial News

Atterocor debuts with $16 million

Newco Atterocor Inc. (Ann Arbor, Mich.) debuted on Friday with $16 million in a series A round led by Frazier Healthcare and 5AM Ventures. Atterocor is developing therapies to treat adrenal cancer. The company said...